Regulation of EBV LMP1-triggered EphA4 downregulation in EBV-associated B lymphoma and its impact on patients' survival

Ya Chi Huang, Sue Jane Lin, Kai Min Lin, Ya Ching Chou, Chung Wu Lin, Shan Chi Yu, Chi Long Chen, Tang Long Shen, Chi Kuan Chen, Jean Lu, Mei Ru Chen, Ching Hwa Tsai

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Epstein-Barr virus (EBV), an oncogenic human virus, is associated with several lymphoproliferative disorders, including Burkitt lymphoma, Hodgkin disease, diffuse large B-cell lymphoma (DLBCL), and posttransplant lymphoproliferative disorder (PTLD). In vitro, EBV transforms primary B cells into lymphoblastoid cell lines (LCLs). Recently, several studies have shown that receptor tyrosine kinases (RTKs) play important roles in EBV-associated neoplasia. However, details of the involvement of RTKs in EBV-regulated B-cell neoplasia and malignancies remain largely unclear. Here, we found that erythropoietinproducing hepatocellular receptor A4 (EphA4), which belongs to the largest RTK Eph family, was downregulated in primary B cells post-EBV infection at the transcriptional and translational levels. Overexpression and knockdown experiments confirmed that EBV-encoded latent membrane protein 1 (LMP1) was responsible for this EphA4 suppression. Mechanistically, LMP1 triggered the extracellular signal-regulated kinase (ERK) pathway and promoted Sp1 to suppress EphA4 promoter activity. Functionally, overexpression of EphA4 prevented LCLs from proliferation. Pathologically, the expression of EphA4 was detected in EBV- tonsils but not in EBV+ PTLD. In addition, an inverse correlation of EphA4 expression and EBV presence was verified by immunochemical staining of EBV+ and EBV- DLBCL, suggesting EBV infection was associated with reduced EphA4 expression. Analysis of a public data set showed that lower EphA4 expression was correlated with a poor survival rate of DLBCL patients. Our findings provide a novel mechanism by which EphA4 can be regulated by an oncogenic LMP1 protein and explore its possible function in B cells. The results provide new insights into the role of EphA4 in EBV+ PTLD and DLBCL.

Original languageEnglish
Pages (from-to)1578-1589
Number of pages12
JournalBlood
Volume128
Issue number12
DOIs
Publication statusPublished - 2016
Externally publishedYes

Fingerprint

Human Herpesvirus 4
Viruses
Lymphoma
Down-Regulation
Survival
Lymphoproliferative Disorders
Lymphoma, Large B-Cell, Diffuse
Cells
B-Lymphocytes
Epstein-Barr Virus Infections
Receptor Protein-Tyrosine Kinases
Membrane Proteins
Oncogenic viruses
Eph Family Receptors
Epstein-Barr virus EBV-associated membrane antigen
Cell Line
Neoplasms
Oncogenic Viruses
Mitogen-Activated Protein Kinase 3
Burkitt Lymphoma

ASJC Scopus subject areas

  • Immunology
  • Biochemistry
  • Hematology
  • Cell Biology

Cite this

Huang, Y. C., Lin, S. J., Lin, K. M., Chou, Y. C., Lin, C. W., Yu, S. C., ... Tsai, C. H. (2016). Regulation of EBV LMP1-triggered EphA4 downregulation in EBV-associated B lymphoma and its impact on patients' survival. Blood, 128(12), 1578-1589. https://doi.org/10.1182/blood-2016-02-702530

Regulation of EBV LMP1-triggered EphA4 downregulation in EBV-associated B lymphoma and its impact on patients' survival. / Huang, Ya Chi; Lin, Sue Jane; Lin, Kai Min; Chou, Ya Ching; Lin, Chung Wu; Yu, Shan Chi; Chen, Chi Long; Shen, Tang Long; Chen, Chi Kuan; Lu, Jean; Chen, Mei Ru; Tsai, Ching Hwa.

In: Blood, Vol. 128, No. 12, 2016, p. 1578-1589.

Research output: Contribution to journalArticle

Huang, YC, Lin, SJ, Lin, KM, Chou, YC, Lin, CW, Yu, SC, Chen, CL, Shen, TL, Chen, CK, Lu, J, Chen, MR & Tsai, CH 2016, 'Regulation of EBV LMP1-triggered EphA4 downregulation in EBV-associated B lymphoma and its impact on patients' survival', Blood, vol. 128, no. 12, pp. 1578-1589. https://doi.org/10.1182/blood-2016-02-702530
Huang, Ya Chi ; Lin, Sue Jane ; Lin, Kai Min ; Chou, Ya Ching ; Lin, Chung Wu ; Yu, Shan Chi ; Chen, Chi Long ; Shen, Tang Long ; Chen, Chi Kuan ; Lu, Jean ; Chen, Mei Ru ; Tsai, Ching Hwa. / Regulation of EBV LMP1-triggered EphA4 downregulation in EBV-associated B lymphoma and its impact on patients' survival. In: Blood. 2016 ; Vol. 128, No. 12. pp. 1578-1589.
@article{a1c0ec30588d4e8f97d980662dd94348,
title = "Regulation of EBV LMP1-triggered EphA4 downregulation in EBV-associated B lymphoma and its impact on patients' survival",
abstract = "Epstein-Barr virus (EBV), an oncogenic human virus, is associated with several lymphoproliferative disorders, including Burkitt lymphoma, Hodgkin disease, diffuse large B-cell lymphoma (DLBCL), and posttransplant lymphoproliferative disorder (PTLD). In vitro, EBV transforms primary B cells into lymphoblastoid cell lines (LCLs). Recently, several studies have shown that receptor tyrosine kinases (RTKs) play important roles in EBV-associated neoplasia. However, details of the involvement of RTKs in EBV-regulated B-cell neoplasia and malignancies remain largely unclear. Here, we found that erythropoietinproducing hepatocellular receptor A4 (EphA4), which belongs to the largest RTK Eph family, was downregulated in primary B cells post-EBV infection at the transcriptional and translational levels. Overexpression and knockdown experiments confirmed that EBV-encoded latent membrane protein 1 (LMP1) was responsible for this EphA4 suppression. Mechanistically, LMP1 triggered the extracellular signal-regulated kinase (ERK) pathway and promoted Sp1 to suppress EphA4 promoter activity. Functionally, overexpression of EphA4 prevented LCLs from proliferation. Pathologically, the expression of EphA4 was detected in EBV- tonsils but not in EBV+ PTLD. In addition, an inverse correlation of EphA4 expression and EBV presence was verified by immunochemical staining of EBV+ and EBV- DLBCL, suggesting EBV infection was associated with reduced EphA4 expression. Analysis of a public data set showed that lower EphA4 expression was correlated with a poor survival rate of DLBCL patients. Our findings provide a novel mechanism by which EphA4 can be regulated by an oncogenic LMP1 protein and explore its possible function in B cells. The results provide new insights into the role of EphA4 in EBV+ PTLD and DLBCL.",
author = "Huang, {Ya Chi} and Lin, {Sue Jane} and Lin, {Kai Min} and Chou, {Ya Ching} and Lin, {Chung Wu} and Yu, {Shan Chi} and Chen, {Chi Long} and Shen, {Tang Long} and Chen, {Chi Kuan} and Jean Lu and Chen, {Mei Ru} and Tsai, {Ching Hwa}",
year = "2016",
doi = "10.1182/blood-2016-02-702530",
language = "English",
volume = "128",
pages = "1578--1589",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "12",

}

TY - JOUR

T1 - Regulation of EBV LMP1-triggered EphA4 downregulation in EBV-associated B lymphoma and its impact on patients' survival

AU - Huang, Ya Chi

AU - Lin, Sue Jane

AU - Lin, Kai Min

AU - Chou, Ya Ching

AU - Lin, Chung Wu

AU - Yu, Shan Chi

AU - Chen, Chi Long

AU - Shen, Tang Long

AU - Chen, Chi Kuan

AU - Lu, Jean

AU - Chen, Mei Ru

AU - Tsai, Ching Hwa

PY - 2016

Y1 - 2016

N2 - Epstein-Barr virus (EBV), an oncogenic human virus, is associated with several lymphoproliferative disorders, including Burkitt lymphoma, Hodgkin disease, diffuse large B-cell lymphoma (DLBCL), and posttransplant lymphoproliferative disorder (PTLD). In vitro, EBV transforms primary B cells into lymphoblastoid cell lines (LCLs). Recently, several studies have shown that receptor tyrosine kinases (RTKs) play important roles in EBV-associated neoplasia. However, details of the involvement of RTKs in EBV-regulated B-cell neoplasia and malignancies remain largely unclear. Here, we found that erythropoietinproducing hepatocellular receptor A4 (EphA4), which belongs to the largest RTK Eph family, was downregulated in primary B cells post-EBV infection at the transcriptional and translational levels. Overexpression and knockdown experiments confirmed that EBV-encoded latent membrane protein 1 (LMP1) was responsible for this EphA4 suppression. Mechanistically, LMP1 triggered the extracellular signal-regulated kinase (ERK) pathway and promoted Sp1 to suppress EphA4 promoter activity. Functionally, overexpression of EphA4 prevented LCLs from proliferation. Pathologically, the expression of EphA4 was detected in EBV- tonsils but not in EBV+ PTLD. In addition, an inverse correlation of EphA4 expression and EBV presence was verified by immunochemical staining of EBV+ and EBV- DLBCL, suggesting EBV infection was associated with reduced EphA4 expression. Analysis of a public data set showed that lower EphA4 expression was correlated with a poor survival rate of DLBCL patients. Our findings provide a novel mechanism by which EphA4 can be regulated by an oncogenic LMP1 protein and explore its possible function in B cells. The results provide new insights into the role of EphA4 in EBV+ PTLD and DLBCL.

AB - Epstein-Barr virus (EBV), an oncogenic human virus, is associated with several lymphoproliferative disorders, including Burkitt lymphoma, Hodgkin disease, diffuse large B-cell lymphoma (DLBCL), and posttransplant lymphoproliferative disorder (PTLD). In vitro, EBV transforms primary B cells into lymphoblastoid cell lines (LCLs). Recently, several studies have shown that receptor tyrosine kinases (RTKs) play important roles in EBV-associated neoplasia. However, details of the involvement of RTKs in EBV-regulated B-cell neoplasia and malignancies remain largely unclear. Here, we found that erythropoietinproducing hepatocellular receptor A4 (EphA4), which belongs to the largest RTK Eph family, was downregulated in primary B cells post-EBV infection at the transcriptional and translational levels. Overexpression and knockdown experiments confirmed that EBV-encoded latent membrane protein 1 (LMP1) was responsible for this EphA4 suppression. Mechanistically, LMP1 triggered the extracellular signal-regulated kinase (ERK) pathway and promoted Sp1 to suppress EphA4 promoter activity. Functionally, overexpression of EphA4 prevented LCLs from proliferation. Pathologically, the expression of EphA4 was detected in EBV- tonsils but not in EBV+ PTLD. In addition, an inverse correlation of EphA4 expression and EBV presence was verified by immunochemical staining of EBV+ and EBV- DLBCL, suggesting EBV infection was associated with reduced EphA4 expression. Analysis of a public data set showed that lower EphA4 expression was correlated with a poor survival rate of DLBCL patients. Our findings provide a novel mechanism by which EphA4 can be regulated by an oncogenic LMP1 protein and explore its possible function in B cells. The results provide new insights into the role of EphA4 in EBV+ PTLD and DLBCL.

UR - http://www.scopus.com/inward/record.url?scp=85015618035&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015618035&partnerID=8YFLogxK

U2 - 10.1182/blood-2016-02-702530

DO - 10.1182/blood-2016-02-702530

M3 - Article

C2 - 27338098

AN - SCOPUS:85015618035

VL - 128

SP - 1578

EP - 1589

JO - Blood

JF - Blood

SN - 0006-4971

IS - 12

ER -